Louise R. Rodino-Klapac, PhD, is President of Research & Development and Technical Operations at Sarepta Therapeutics. She has dedicated her career to developing genetic medicines for rare, life limiting diseases, including Duchenne muscular dystrophy, where her work contributed to the first approved gene therapy.
